Contribution: Industrial Research Assistance Program – Contributions to Firms
Qu Biologics Inc.
$38,170.00
COVID-19 Rapid Response: Novel Immune Therapeutic for the Prevention and Treatment of COVID-19
FY 2020-21 · 2020-08-17
Summary
Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specific Immunomodulator (SSI), for use in a planned clinical trial for COVID-19 prevention.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
842333817
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-08-17 | 2020-21 | $350,000.00 |
| 2 | 2020-08-17 | 2020-21 | $38,170.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 59 days. The total amended value is -311,830 dollars.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 59 jours. La valeur totale des modifications est de - 311 830 dollars.
Agreement End Date
2021-03-31
Agreement Number
955668
Agreement Start Date
2020-08-17
Agreement Title
COVID-19 Rapid Response: Novel Immune Therapeutic for the Prevention and Treatment of COVID-19
Agreement Title (French)
Réponse rapide face à la COVID-19 : Nouvelle immunothérapie pour la prévention et le traitement de la COVID-19
Agreement Type
Contribution
Agreement Value
$38,170.00
Amendment Date
2021-02-22
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specific Immunomodulator (SSI), for use in a planned clinical trial for COVID-19 prevention.
Description (French)
Élaborer des processus et des méthodes d'analyse de contrôle de la qualité et de manipulation aseptique de réactifs et de produits, en vue de la production en masse à l'échelle commerciale de QBKPN, l'immunomodulateur spécifique au site (ISS) ciblé sur les poumons, de l'entreprise aux fins d'utilisation dans un essai clinique prévu pour la prévention de la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby South
Federal Riding (French)
Burnaby-Sud
Federal Riding Number
59003
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
842333817
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
Qu Biologics Inc.
Recipient Postal Code
V5G 4X4
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q2-955668
